Edition:
United States

BioDelivery Sciences International Inc (BDSI.OQ)

BDSI.OQ on NASDAQ Stock Exchange Capital Market

3.58USD
14 Nov 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$3.58
Open
$3.62
Day's High
$3.69
Day's Low
$3.43
Volume
148,979
Avg. Vol
77,391
52-wk High
$4.14
52-wk Low
$1.70

Latest Key Developments (Source: Significant Developments)

Biodelivery Sciences International Files For Mixed Shelf Of Up To $150 Mln
Friday, 9 Nov 2018 09:46am EST 

Nov 9 (Reuters) - BioDelivery Sciences International Inc ::BIODELIVERY SCIENCES INTERNATIONAL INC FILES FOR MIXED SHELF OF UPTO $150 MILLION - SEC FILING.  Full Article

BioDelivery Sciences Announces Agreement With Broadfin Capital On Comprehensive Plan To Strengthen Business
Thursday, 17 May 2018 08:01am EDT 

May 17 (Reuters) - BioDelivery Sciences International Inc ::BIODELIVERY SCIENCES ANNOUNCES AGREEMENT WITH BROADFIN CAPITAL ON COMPREHENSIVE PLAN TO STRENGTHEN BUSINESS.BIODELIVERY SCIENCES INTERNATIONAL INC - $50 MILLION EQUITY FINANCING IS BEING LED BY BROADFIN CAPITAL.BIODELIVERY SCIENCES INTERNATIONAL - HAS ENTERED INTO AGREEMENT WITH AFFILIATE OF BROADFIN CAPITAL TO RECONSTITUTE BDSI'S BOARD.BIODELIVERY SCIENCES INTERNATIONAL INC - DEALS EXTEND BDSI'S CASH RUNWAY THROUGH 2020.BIODELIVERY SCIENCES INTERNATIONAL INC - AMENDS SENIOR CREDIT FACILITY WITH CRG.BIODELIVERY SCIENCES INTERNATIONAL INC - THREE NEW INDEPENDENT DIRECTORS SELECTED BY BROADFIN ADDED TO BOARD.BIODELIVERY SCIENCES - UNDER AGREEMENT, AT CLOSING, BROADFIN MANAGING PARTNER KEVIN KOTLER TO JOIN CO'S BOARD, WITH TODD DAVIS, PETER GREENLEAF.BIODELIVERY SCIENCES INTERNATIONAL INC - FOUR CURRENT INDEPENDENT DIRECTORS RETIRING.BIODELIVERY SCIENCES INTERNATIONAL INC - AMENDS SENIOR CREDIT FACILITY WITH CRG, WHICH INCLUDES PUSHING OUT PRINCIPAL DEBT REPAYMENT TO 2021.BIODELIVERY SCIENCES - BROADFIN WILL WITHDRAW NOTICE OF NOMINATION OF PERSONS FOR ELECTION AS DIRECTORS AT BDSI'S STOCKHOLDERS MEETING.BIODELIVERY SCIENCES INTERNATIONAL INC - BROADFIN ALSO AGREED TO VOTE ITS SHARES AT ANNUAL MEETING FOR BDSI'S DIRECTOR NOMINEES.BIODELIVERY SCIENCES INTERNATIONAL - BROADFIN ALSO AGREED TO CERTAIN CUSTOMARY STANDSTILL RESTRICTIONS.  Full Article

BioDelivery Sciences Appoints Herm Cukier As CEO
Monday, 7 May 2018 09:00am EDT 

May 7 (Reuters) - BioDelivery Sciences International Inc ::BIODELIVERY SCIENCES APPOINTS HERM CUKIER AS CHIEF EXECUTIVE OFFICER.BIODELIVERY SCIENCES INTERNATIONAL INC - FORMER PRESIDENT AND CEO MARK A. SIRGO WILL CONTINUE HIS ROLE AS VICE CHAIRMAN OF BOARD OF DIRECTORS.  Full Article

BioDelivery Sciences Reacquires Onsolis From Collegium Pharmaceutical
Thursday, 14 Dec 2017 04:30pm EST 

Dec 14 (Reuters) - BioDelivery Sciences International Inc ::BIODELIVERY SCIENCES REACQUIRES ONSOLIS® FROM COLLEGIUM PHARMACEUTICAL.BIODELIVERY SCIENCES - GOT 90-DAY NOTICE FROM COLLEGIUM REGARDING TERMINATION OF LICENSE AND DEVELOPMENT AGREEMENT FOR ONSOLIS.BIODELIVERY SCIENCES INTERNATIONAL - TERMINATION OF AGREEMENT WILL BE EFFECTIVE ON MARCH 8, 2018.BIODELIVERY SCIENCES - COLLEGIUM TO TERMINATE LICENSE DUE TO ITS AGREEMENT TO COMMERCIALIZE NUCYNTA IMMEDIATE RELEASE, NUCYNTA ER.BIODELIVERY SCIENCES - "WE WILL BE ASSESSING OPTIONS FOR COMMERCIALIZING ONSOLIS".BIODELIVERY SCIENCES - DO NOT CURRENTLY BELIEVE RETURN OF ONSOLIS TO US WILL HAVE MATERIAL IMPACT ON BUSINESS.  Full Article

BioDelivery Sciences Says ‍Ohio Workers Compensation Approved Change To Formulary
Monday, 27 Nov 2017 07:00am EST 

Nov 27 (Reuters) - BioDelivery Sciences International Inc ::BIODELIVERY SCIENCES - ‍OHIO BUREAU OF WORKERS COMPENSATION APPROVED CHANGE TO ITS FORMULARY RESULTING IN FAVORABLE POSITIONING FOR BELBUCA, BUNAVAIL.BIODELIVERY SCIENCES INTERNATIONAL INC - ‍BELBUCA WILL BE ADDED TO FORMULARY AS A TIER 1 LONG-ACTING OPIOID WITHOUT RESTRICTIONS​.BIODELIVERY SCIENCES INTERNATIONAL INC - ‍CHANGES TO FORMULARY WILL GO INTO EFFECT APRIL 1, 2018​.  Full Article

BioDelivery Sciences reports Q3 loss per share $0.21
Thursday, 9 Nov 2017 04:01pm EST 

Nov 9 (Reuters) - BioDelivery Sciences International Inc :BioDelivery Sciences reports third quarter 2017 financial results and provides corporate update.Q3 loss per share $0.21.Q3 revenue $11.3 million versus I/B/E/S view $9.4 million.Q3 earnings per share view $-0.22 -- Thomson Reuters I/B/E/S.  Full Article

BioDelivery sciences announces patent litigation settlement agreement with Teva
Thursday, 12 Oct 2017 07:00am EDT 

Oct 12 (Reuters) - Biodelivery Sciences International Inc :BioDelivery Sciences announces patent litigation settlement agreement with Teva.BioDelivery Sciences International Inc - ‍other terms of agreement are confidential​.BioDelivery Sciences - ‍as part of settlement agreement, co has entered into a non-exclusive license agreement with Teva ​.BioDelivery Sciences International - ‍ entered into settlement agreement with Teva Pharmaceuticals USA, Actavis Laboratories Ut, Teva Pharmaceuticals Industries.BioDelivery Sciences International Inc - ‍as part of settlement agreement BDSI has entered into a non-exclusive license agreement with Teva​.BioDelivery Sciences - settlement agreement permits Teva to first begin selling its generic version of BUNAVAIL in U.S. On July 23, 2028 or earlier under certain circumstances.BioDelivery Sciences International - ‍ settlement agreement resolves BDSI's BUNAVAIL patent litigation against Teva pending in United States district court​.BioDelivery Sciences - ‍agreement with Teva permits Teva to first begin selling generic version of BUNAVAIL in U.S. On July 23, 2028 or earlier​.  Full Article

BioDelivery Sciences Q4 loss per share $0.29
Friday, 17 Mar 2017 06:30am EDT 

Biodelivery Sciences International Inc : Biodelivery sciences provides corporate update and reports fourth quarter and full-year 2016 financial results . Q4 loss per share $0.29 . Q4 revenue $3.9 million versus i/b/e/s view $3.9 million . Q4 earnings per share view $-0.26 -- Thomson Reuters I/B/E/S . Biodelivery sciences international inc - intend to evaluate an array of belbuca-related business and commercial partnership opportunities . Biodelivery sciences international inc - expect approval of belbuca in canada in first half of 2017 .Biodelivery sciences international inc- had cash and cash equivalents of approximately $32.0 million at december 31, 2016..  Full Article

BRIEF-BioDelivery Sciences Announces Closing Of $50 Mln Equity Financing; Appointment Of Peter Greenleaf As Chairman

* BIODELIVERY SCIENCES ANNOUNCES CLOSING OF $50 MILLION EQUITY FINANCING AND APPOINTMENT OF PETER GREENLEAF AS CHAIRMAN OF THE BOARD Source text for Eikon: Further company coverage: